WST Price Prediction Next Week
Technical Analysis: WST experienced a significant drop of 33.22% after reporting Q4 results and providing weaker-than-expected 2025 guidance. However, the stock showed strong recovery on Friday, rising 7.84% to $214.73 despite broader market weakness.
Current technical indicators show:
- RSI(14) at 18.98 indicates severely oversold conditions
- MACD is negative at -19.32 with bearish divergence
- Stock trading below all major moving averages (5,10,20,60,200-day)
Fundamental Catalysts:
- Deutsche Bank upgraded WST from Hold to Buy with a $250 price target
- Q4 earnings beat expectations with EPS of $1.82 vs $1.72 estimate
- However, 2025 guidance disappointed:
- Revenue guidance: $2.88-2.91B vs $3.04B expected
- Adjusted EPS guidance: $6.00-6.20 vs $7.44 expected
Price Projection for Next Week: Based on technical analysis and recent events:
- Support levels: $201.86 (Friday's low)
- Resistance levels: $223.44 (Friday's high)
- Fibonacci pivot points suggest next resistance at $225.52
Trading Recommendation: SELL with target price of $195-200 range for next week because:
- Despite Friday's bounce, negative momentum from earnings disappointment likely to continue
- Weak 2025 guidance suggests continued pressure on margins
- Technical indicators show bearish trend despite oversold conditions
- Stock remains below all major moving averages indicating sustained downward pressure
WST Similar Chart Price Prediction
The price of WST is predicted to go up -7.59%, based on the high correlation periods with DRVN. The similarity of these two price pattern on the periods is 98.73%.
WST
DRVN
Down: -7.59%Similarity: 98.73%
WST Revenue Forecast
WST EPS Forecast
WST FAQs
What is bull’s view on WST?
What is bear's view on WST?
What is WST revenue forecast for next quarter？
What is WST eps forecast for next quarter？
WST VS S&P500
West's top-line growth is likely to be buoyed by secular trends in injectable drugs, especially increasing use of biologic drugs.
West is a potential beneficiary of the rapidly growing GLP-1 obesity drug market, which is an injectable drug, although the magnitude of long-term benefit to West is unclear at this time.
Due to more stringent regulations and increased use of biologics, customers may be incentivized to switch from standard components to high value products, which improves West's profit margins.
WST Analyst's Forecast
Paul Knight
Keybanc
Buy
2025-02-14
Price Target
$470 → $325
Upside
+51.35%
KeyBanc analyst Paul Knight lowered the firm's price target on West Pharmaceutical to $325 from $470 to reflect lower FY25 estimates and confidence in long-term fundamentals, while keeping an Overweight rating on the shares. The firm notes West beat Q4 expectations, but the stock is down significantly due to disappointing FY25 guidance of 2%-3% organic growth vs. KeyBanc at +7.2% and the Street at 6.1%.
Thomas Palmer
Citigroup
Strong Buy
2025-01-08
Price Target
$400
Upside
+18.73%
Derik De Bruin
B of A Securities
Strong Buy
2024-12-13
Price Target
$350 → $355
Upside
+7.56%
